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ABSTRACT
The prefrontal cortex and information processing:
nitric oxide signaling studied in an animal model of schizophrenia
The prefrontal cortex has been extensively linked to several cognitive domains that are 
severely compromised in schizophrenia. It has therefore become a key region for studies 
on the disabling cognitive dysfunction commonly observed in patients with schizophrenia. 
The absence of effective treatment options for cognitive deficits makes the identification 
of novel drug targets urgent, and this search is largely dependent on validated animal 
models. Administration of the NMDA receptor antagonist phencyclidine (PCP) has proven 
effective in mimicking several features of schizophrenia, including disrupted information 
processing and aberrant prefrontal cortex function. Previous studies show that a range of 
cognition-related behavioral deficits induced by PCP in experimental animals, including 
impaired pre-attentive information processing as measured by prepulse inhibition (PPI), 
can be blocked by inhibiting the production of nitric oxide (NO). The aim of the present 
thesis was to study the role of prefrontal NO signaling in the effects of PCP on information 
processing. Measurements of NO and its main effector, cGMP, were performed using in 
vivo voltammetry and microdialysis. This was combined with PPI and locomotor activity studies 
following pharmacological modulation of NO and GABA signaling. Systemic administration 
of PCP to mice disrupted PPI, which was blocked in a dose-dependent manner by inhibiting 
substrate availability for NO synthase using L-lysine, and by micro injections of an inhibitor 
of cGMP synthesis into the mouse medial prefrontal cortex. Further more, PCP caused an 
increase in prefrontal cGMP levels that was blocked by the NO synthase inhibitor, L-NAME. 
Similarly, prefrontal NO release, as measured by a novel microelectrochemical sensor, was 
increased by PCP, and this increase was blocked by pretreatment with L-NAME in the rat. 
Finally, systemic pretreatment with a combination of sub-threshold doses of the GABA
B
 
agonist baclofen, and L-NAME, increased PPI per se, and prevented the effects of PCP on 
PPI. On a regional level, prefrontal microinjections with baclofen fully blocked the effects 
of PCP on PPI in mice, and NO levels in the rat prefrontal cortex were decreased following 
systemic baclofen administration. In conclusion, the present thesis presents biochemical 
and behavioral support for the involvement of a prefrontal NO/cGMP signaling pathway 
in the effects of PCP. Furthermore, this mechanism may partly be explained by a decrease 
in inhibitory power of GABAergic interneurons, followed by increased NO signaling in the 
prefrontal cortex. Thus, studies of GABA/NO interactions in the prefrontal cortex may 
prove valuable when searching for novel treatment targets for cognitive dysfunction in 
schizophrenia.
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